ライフサイエンスコーパス: A(2) receptor

1 .g., human platelet thrombin and thromboxane A2 receptors.

2 increase in Galphaq coupling to thromboxane A2 receptors.

3 n increase in ligand affinity of thromboxane A2 receptors.

4 tinguishable from human platelet thromboxane A2 receptors.

5 may mediate the desensitization of adenosine A2 receptors.

6 tent with the activation of ocular adenosine A2 receptors.

7 lly reversed by blockade of adenosine A1 and A2 receptors.

8 structural model for a GPCR, the thromboxane A(2) receptor.

9 is a homolog of the mammalian phospholipase A(2) receptor.

10 a phosphoproteins co-purify with thromboxane A(2) receptors.

11 Antibodies against phospholipase A(2) receptor 1 (PLA(2)R1) are found in 80% of patients

12 podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-c

13 Phospholipase A2 receptor 1 (PLA2R) is a target autoantigen in 70% of

14 ive until 2009 when the M-type phospholipase A2 receptor 1 (PLA2R) was identified as a disease autoan

15 jor target antigen, the M-type phospholipase A2 receptor 1 (PLA2R).

16 the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) and the recently identified throm

17 Phospholipase A2 receptor 1 (PLA2R1) is a 180-kDa transmembrane protei

18 ) along with the major antigen phospholipase A2 receptor 1 (PLA2R1).

19 ith autoantibodies against the phospholipase A2 receptor 1 (PLA2R1).

20 us nephropathy target antigens phospholipase A2 receptor 1 and thrombospondin type 1 domain-containin

21 ntibodies targeting the M-type phospholipase A2 receptor-1 (PLA2R) on the surface of glomerular visce

22 clinical scenario, focusing on phospholipase A2 receptor; ( 2 ) one antigen!=one clinical condition,

23 the ortholog of the mammalian phospholipase A2 receptor, a mannose receptor family member, rather th

24 In the central nervous system, noradrenergic a2 receptors (a2-ARs) are widely expressed in the motor

25 DPMA, an adenosine A2 receptor (A2R) agonist, decreased KDR mRNA in a dose-

26 imulatory concentrations; however, adenosine A2 receptor (A2R) agonists DPMA, NECA, and CGS21680 incr

27 or prosurvival GsPCRs, we explored adenosine-A2-receptor (A2R), CGRPR (calcitonin-gene-related-peptid

28 5'-(N-ethylcalboxamido)-adenosine (adenosine A2 receptor [A2R] agonists, Kd = 15 and 16 nmol/l, respe

29 on of PKC can block the effects of adenosine A2 receptor activation by CGS-21680 on anoxia and reoxyg

30 A1 receptor activation, the implications of A2 receptor activation on synaptic transmission have not

31 d which inhibits neutrophil function through A2 receptor activation.

32 The A(2) receptor agonist 2-p-(2-carboxylethyl)-phenylamino-

33 The adenosine A(2) receptor agonist, CGS-21680, and DB-cAMP decreased

34 o-adenosine (NECA), a nonselective adenosine A(2) receptor agonist, or with 2-[p-(2-carboxyethyl)-phe

35 The adenosine A2 receptor agonist 5'-(N-cyclopropyl)-carboxamidoadenos

36 stimulated O2.- generation by the adenosine A2 receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA

37 The selective adenosine A2 receptor agonist DPMA (10 micromol/L) decreased TNF-a

38 an platelets by thrombin and the thromboxane A2 receptor agonist U46619 lead to phosphorylation of Ga

39 vasoconstriction induced by the thromboxane A2 receptor agonist U46619, which suggest a NO-independe

40 enosine (CGS-21680 [20 nmol/L], an adenosine A2 receptor agonist, R-(--)-N6-(2-phenylisopropyl)-adeno

41 ated by adenosine (10 microM, 2 min) and the A2-receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5

42 livers were treated with adenosine A(1) and A(2) receptor agonists or dibutyryl-cyclic adenosine mon

43 13) (of the G(12) family) by the thromboxane A(2) receptor alpha (TPalpha), via agonist-effected [(35

44 ne granular co-localization of Phospholipase A(2) receptor and IgG evident on transplant biopsy on da

45 Reactivity for phospholipase A2 receptor and thrombospondin type 1 domain containing

46 The effect appears to be mediated by the A2 receptor and transduced through a G protein-adenylyl

47 demonstrated expression of the phospholipase A2 receptor and two G-protein-coupled receptors for LPC

48 y requires adenosine activation of adenosine A2 receptors and is mediated by beta gamma dimers.

49 acting to increase O2 delivery via adenosine A2 receptors and to decrease metabolic rate via A1 recep

50 8-cyclopentyltheophylline (CPT), but not the A(2) receptor antagonist 3, 7-dimethyl-1-propargylxanthi

51 In contrast, a highly specific A2 receptor antagonist (10(-7) or 10(-5) M) had no effec

52 yl-1, 3-dipropylxanthine (DPCPX) but not the A2 receptor antagonist 3, 7-dimethyl-1-propargylxanthine

53 or inhibition of adenosine by the adenosine A2 receptor antagonist 3,7-dimethyl-1-propargylxanthine

54 nists and AP-5 were reversed by an adenosine A2 receptor antagonist administered intraperitoneally.

55 lished by administration of the adenosine A1/A2 receptor antagonist PD 115,199 (3 mg/kg i.v.) before

56 Aspirin and the thromboxane A2 receptor antagonist SQ29548 inhibited activation of t

57 After pretreatment with the thromboxane A2 receptor antagonist SQ30, 741, the vasoconstrictor re

58 ected by 3,7-dimethy-1-propargylxanthine, an A2 receptor antagonist.

59 se of ticagrelor followed by an adenosine A1/A2-receptor antagonist [8-(p-sulfophenyl)theophylline, 4

60 ase, in the presence of the adenosine A1 and A2 receptor antagonists 8-cyclopentyl-1,3-dipropylxanthi

61 r agonist CGS-21680 (50% closure by day 2 in A2 receptor antagonists.

62 of L-arginine transport was inhibited by the A2-receptor antagonists ZM-241385 and 3,7-dimethyl-1-pro

63 hyl ester (an NO synthase inhibitor) and the A2-receptor antagonists ZM-241385 and DMPX prevented inc

64 circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic poly

65 most cases associated with anti-phospholipid A2 receptor antibodies (antiPLA2R).

66 P = 0.010] and those with anti-phospholipase A2 receptor antibodies [hazard ratio = 3.761 (1.635-8.65

67 most cases associated with antiphospholipid A2 receptor antibodies.

68 Rates of antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) depletion in NIAT-r

69 active against a polyclonal anti-thromboxane A2 receptor antibody.

70 riments tested the hypothesis that adenosine A2 receptors are involved in central reward function.

71 AMP increased phosphorylation of thromboxane A(2) receptor-associated Galpha(13) by 87 +/- 27%.

72 This is a very early case of Phospholipase A(2) receptor-associated recurrent membranous nephropath

73 isease is associated with anti-Phospholipase A(2) receptor autoantibodies.

74 rculating levels of serum anti-Phospholipase A(2) receptor autoantibody that declined over time in co

75 hropathy with circulating anti-Phospholipase A(2) receptor autoantibody, which supports the emerging

76 Anti-phospholipase A2 receptor autoantibody (PLA2R-Ab) plays a critical rol

77 Adenosine A(2) receptor blockade prevented the protective effect o

78 A2 receptor blockade by the A2 antagonist, DMPX (3,7-dim

79 A2 receptor blockade in the presence of complete A1 rece

80 nase inhibition with aspirin and thromboxane A2 receptor blockade with ifetroban on the chronic vasod

81 D2 or adenosine A2 receptor blockade, pertussis toxin, Rp-cAMPS, or over

82 ling of Galpha(13) with platelet thromboxane A(2) receptors but destabilized coupling of Galpha(13) t

83 EP4, prostaglandin F2alpha, and thromboxane A2 receptors but not anti-inflammatory EP2, prostaglandi

84 onists, including caffeine, or targeting the A2 receptors by siRNA pretreatment of T cells improved t

85 uency test pulses (0.033 Hz) indicating that A2 receptors can enhance synaptic transmission.

86 Blockade of thromboxane A(2) receptor did not affect the serotonin response in a

87 elet aggregation via stimulation of platelet A(2) receptors) during brief I/R contributes to this imp

88 Agents active at A2 receptors either were without effect or could be bloc

89 The erythropoietin-producing hepatoma A2 receptor (EphA2) is a tyrosine kinase overexpressed b

90 The reduced form of the thromboxane A(2) receptor experienced a decrease in ligand binding a

91 nd activation of the signal molecules ephrin-A2 receptor, FAK, Src, and Rac1.

92 ntegrin molecules and tyrosine kinase ephrin-A2 receptor, followed by the activation of preexisting i

93 A2 receptors for extracellular adenosine might act as bo

94 mediates phosphorylation of the thromboxane A(2) receptor-G-protein complex.

95 y chromatography purification of thromboxane A(2) receptor-G-protein complexes from these membranes r

96 mammalian counterpart and is a phospholipase A(2) receptor homolog.

97 ate the presence of a functional thromboxane A2 receptor in oligodendrocytes and are consistent with

98 ons indicating a high density of thromboxane A2 receptors in myelinated brain and spinal cord fiber t

99 The presence of functional thromboxane A2 receptors in neonatal rat oligodendrocytes and human

100 The human platelet thromboxane A2 receptor is a member of the G-protein-coupled superfa

101 increase of the transmembrane Ectodysplasin-A2-Receptor is a prominent tissue-independent alteration

102 oward the extracellular domain of the ephrin A2 receptor, long circulation half-life (8-12 h) in mous

103 Together, these results suggest that the A2 receptors may play an important role in the induction

104 the protective effects of adenosine include A2-receptor mediated vasodilation, A1-receptor mediated

105 s, but the latter is dominant in thromboxane A(2) receptor-mediated contraction.

106 consequent suppression of slow AHPs, or (2) A(2)-receptor-mediated elevation of cAMP directly suppre

107 e considered two alternative hypotheses: (1) A(2)-receptor-mediated suppression of I(Ca) leading to s

108 y of the novel antagonist N-0861, the A1 and A2 receptor-mediated cardiac effects of adenosine were i

109 8-chlorostyrylcaffeine (CSC), suggesting an A2 receptor-mediated mechanism.

110 nstriction in vivo, which is often masked by A2 receptor-mediated vasodilation.

111 ed NDNF, while IgG eluate from phospholipase A2 receptor-MN showed no binding.

112 50 cases (discovery cohort) of phospholipase A2 receptor-negative MN to identify novel target antigen

113 Donor-derived MN is rare, phospholipase A2 receptor-negative, and can still be encountered in li

114 tis or antinephrin/anti-M-type phospholipase A2 receptor-nephrotic syndrome.

115 n natriuretic peptide], EDA2R [ectodysplasin A2 receptor], NPPB [B-type natriuretic peptide], BCAN [b

116 ine diminishes inflammation via occupancy of A2 receptors on inflammatory cells.

117 In conclusion, an adenosine A(2) receptor pathway coupled to increased cAMP mediates

118 rcomeric DCM, including EDA2R (ectodysplasin A2 receptor; per log2 fold change in relative protein ab

119 Autoantibodies to the M-type phospholipase A(2) receptor (PLA(2)R) are sensitive and specific for i

120 The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in i

121 otein band detected the M-type phospholipase A(2) receptor (PLA(2)R).

122 n who tested positive for anti-phospholipase A(2) receptor (PLA2R) antibodies, the decline in autoant

123 rular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-con

124 The phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-con

125 d pretransplant levels of anti-phospholipase A2 receptor (PLA2R) antibodies were strongly associated

126 ard with the identification of phospholipase A2 receptor (PLA2R) as a target antigen in the majority

127 Identification of the phospholipase A2 receptor (PLA2R) as the major antigen in adults in 20

128 The characterization of the phospholipase A2 receptor (PLA2R) as the major target antigen in prima

129 The muscle-type phospholipase A2 receptor (PLA2R) has been identified as the principal

130 Phospholipase A2 receptor (PLA2R) is a member of the mannose receptor

131 The M-type phospholipase A2 receptor (PLA2R) is expressed in podocytes in human g

132 The M-type phospholipase A2 receptor (PLA2R) is the major autoantigen of primary

133 Secretory phospholipase A2 receptor (PLA2R) is the target antigen of the auto-an

134 was determined by ELISA using phospholipase A2 receptor (PLA2R) or Gd-IgA1 as antigen.

135 ht to determine the utility of phospholipase A2 receptor (PLA2R) staining for the detection of recurr

136 ranous nephropathy are against phospholipase A2 receptor (PLA2R), a cell surface receptor.

137 Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (M

138 ve IgG4 autoantibodies against phospholipase A2 receptor (PLA2R).

139 ing IgG4 autoantibodies to the phospholipase A2 receptor (PLA2R).

140 oantibodies against the M-type phospholipase A2 receptor (PLA2R-AB) are a key biomarker in the diagno

141 ic variants in an HLA-DQA1 and phospholipase A2 receptor (PLA2R1) allele associate most significantly

142 oantibodies against the M-type phospholipase A2 receptor (PLA2R1) expressed on kidney podocytes, but

143 The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopat

144 The phospholipase A2 receptor (PLA2R1) is the major autoantigen in primary

145 out the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein.

146 the physiological role of the phospholipase A2 receptor (PLA2R1).

147 We examined the role adenosine A2 receptors play in the efficacy of neurotransmission b

148 45 min following the tetanus indicating that A2 receptors play no significant role in the maintenance

149 It has been shown in phospholipase A2 receptor positive membranous nephropathy that known a

150 racellular cAMP levels through activation of A2 receptors present on developing amacrine and ganglion

151 tion as the second intron of the thromboxane A2 receptor, prostaglandin D2 receptor, prostaglandin I2

152 -2-enoyl-coenzyme A reductase, phospholipase A2 receptor, protein kinase C zeta type, tubulin beta-4B

153 tor-beta binding protein 2 and ectodysplasin A2 receptor showed the strongest mediation across cohort

154 show that strengthening of the Ectodysplasin-A2-Receptor signalling axis in myogenic precursors and d

155 The G(q)-coupled thromboxane A(2) receptor subtype, TPalpha, and G(i)-coupled TPbeta

156 he effects of adenosine and adenosine Al and A2 receptor subtype agonists on in vitro perfused contro

157 ing the prognostic value of antiphospholipid A2 receptor, the risk of living-related donation, the li

158 creases Galphaq association with thromboxane A2 receptors thereby shifting them to a higher affinity

159 probably mediated by activation of adenosine A2 receptors through the PKC pathway, and (3) the preser

160 from astrocytes by a direct effect on A1 and A2 receptors, thus providing a link between actions of N

161 HHV-8 uses langerin and the ephrin A2 receptor to infect Langerhans cells, which support fu

162 vasodilatation, and stimulates carotid body A2 receptors to increase respiration.

163 eased by acute hypoxia stimulates A1 but not A2 receptors to produce muscle vasodilatation, and stimu

164 Thromboxane A(2) receptor (TP receptor), a prostanoid receptor, belo

165 The thromboxane (TX) A(2) receptor (TP) encompasses two alternatively spliced

166 extracellular loop (eLP2) of the thromboxane A(2) receptor (TP) had been proposed to be involved in l

167 The thromboxane A(2) receptor (TP) is a G protein-coupled receptor that

168 Thromboxane synthase (TXAS) and thromboxane A(2) receptor (TP), two critical components for thrombox

169 harmacological inhibition of the thromboxane A(2) receptor (TP).

170 F2alpha receptor (FP) (61), and thromboxane A2 receptor (TP) (11) while sparing EP2, EP3, and prosta

171 he PGF2 alpha receptor (FP), the thromboxane A2 receptor (TP) and the prostacyclin receptor (IP).

172 lexibility of the purified human thromboxane A2 receptor (TP) was characterized by spectroscopic appr

173 Human thromboxane A2 receptor (TP), a G protein-coupled receptor (GPCR), i

174 date the molecular mechanisms of thromboxane A2 receptor (TP)-induced insulin resistance in endotheli

175 Here, we show that vasopressive thromboxane A2 receptors (TP) can intimately couple with and inhibit

176 We explore here, using the thromboxane A2 receptor TPalpha, the ability of G12 and G13 to repor

177 tors; two splice variants of the thromboxane A2 receptor (TPalpha and TPbeta) have been cloned.

178 n of the signaling properties of thromboxane A2 receptor (TPalpha) -Galpha12 and -Galpha13 fusion con

179 g partner of the beta-isoform of thromboxane A2 receptor (TPbeta) by yeast two-hybrid screening.

180 Thromboxane A2 receptor (TPr) stimulation induces cellular hypertrop

181 tion, and functional coupling to thromboxane A(2) receptors (TPRs) during oligodendrocyte (OLG) devel

182 uced by arachidonic acid and the thromboxane A(2) receptor (TxA(2)R) agonist U46619 were reduced in P

183 oxidative stress, activates the thromboxane A2 receptor (TXAR) and the Rho-associated kinase (ROCK)

184 ing effect could be mediated by an adenosine A2 receptor via the protein kinase C (PKC) pathway.

185 d be inhibited by an antagonist of adenosine A(2) receptors, whereas, in contrast, (3) brief vascular

186 tal cardiomyocytes expressed the thromboxane A(2) receptor, whose activation induced a metabolic shif

187 elated, but distinct, X-linked ectodysplasin-A2 receptor (XEDAR).